A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus
← catalyst calendarNCT07465224 · readout in 282 d
Sponsored by Alnylam Pharmaceuticals (industry) · ALNY — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
24estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-01-15 | actual | When the study began enrolling |
| Primary completion | 2027-05-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-05-28 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Type 2 Diabetes Mellitus (T2DM)
Interventions
- Drug: ALN-4324
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFChange from Baseline in M-value
measured Baseline up to Month 3
Permalink · ALNY's whole pipeline · Catalyst calendar · Every registered study · What changed